Talphera, Inc. (TLPH)
0.7852
+0.05
(+6.25%)
USD |
NASDAQ |
Nov 20, 16:00
0.7853
0.00 (0.00%)
After-Hours: 20:00
Talphera Research and Development Expense (TTM) : 7.09M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 7.09M |
| June 30, 2026 | 6.704M |
| March 31, 2026 | 6.514M |
| December 31, 2025 | 6.033M |
| September 30, 2025 | 5.795M |
| June 30, 2025 | 6.045M |
| March 31, 2025 | 6.454M |
| December 31, 2024 | 6.718M |
| September 30, 2024 | 7.068M |
| June 30, 2024 | 6.193M |
| March 31, 2024 | 5.572M |
| December 31, 2023 | 5.139M |
| September 30, 2023 | 4.492M |
| June 30, 2023 | 3.689M |
| March 31, 2023 | 2.655M |
| December 31, 2022 | 2.45M |
| September 30, 2022 | 2.41M |
| June 30, 2022 | 3.451M |
| March 31, 2022 | 3.921M |
| December 31, 2021 | 4.095M |
| September 30, 2021 | 3.945M |
| June 30, 2021 | 3.485M |
| March 31, 2021 | 3.574M |
| December 31, 2020 | 4.017M |
| September 30, 2020 | 4.244M |
| Date | Value |
|---|---|
| June 30, 2020 | 4.346M |
| March 31, 2020 | 4.696M |
| December 31, 2019 | 4.661M |
| September 30, 2019 | 6.302M |
| June 30, 2019 | 8.886M |
| March 31, 2019 | 11.00M |
| December 31, 2018 | 13.14M |
| September 30, 2018 | 14.11M |
| June 30, 2018 | 14.38M |
| March 31, 2018 | 16.00M |
| December 31, 2017 | 19.41M |
| September 30, 2017 | 22.07M |
| June 30, 2017 | 22.77M |
| March 31, 2017 | 24.15M |
| December 31, 2016 | 21.40M |
| September 30, 2016 | 18.55M |
| June 30, 2016 | 19.32M |
| March 31, 2016 | 20.35M |
| December 31, 2015 | 22.49M |
| September 30, 2015 | 26.29M |
| June 30, 2015 | 26.14M |
| March 31, 2015 | 26.12M |
| December 31, 2014 | 24.52M |
| September 30, 2014 | 21.56M |
| June 30, 2014 | 22.86M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Relmada Therapeutics, Inc. | 33.77M |
| Journey Medical Corp. | 0.259M |
| ANI Pharmaceuticals, Inc. | 50.60M |
| Corcept Therapeutics, Inc. | 241.72M |
| Veru, Inc. | 11.76M |